(Total Views: 2260)
Posted On: 05/24/2020 12:44:03 AM
Post# of 153916
Techguru and Boatbuilder, Leronlimab discussed in Brasil medical study:
As Brasil has the most death toll in South America, this could be the next country to take action with Leronlimab to fight Covid-19.
Excerpt:
As shown in Table 3, a multiplicity of immunosuppressive drugs or
therapies have been used to reverse the cytokine release syndrome in Covid-19 trials. The tested immunomodulating and/or anti-inflammatory drugs cover a broad range of compounds and modes of action such as classical glucocorticoids or agonists of glucocorticoid receptor (dexamethasone, methylprednisolone, budesonide), biologicals including some of the newest ones (anti-IL-6 monoclonal antibodies tocilizumab and siltuximab, the antibody against CCR5 receptors on T-lymphocytes leronlimab , and an antibody against cytokine fusion protein CD24Fc), ruxolitinib (Janus kinase JAK1 and JAK2 selective inhibitor and blocker of cytokine signalling)
Table 3:
Leronlimab (PRO 140)
Antibody against chemokine CCR5 receptor on T-lymphocytes. Used to treat HIV infections
Severe or critical Covid-19 patients Q (n = 75, n = 390)
https://visaemdebate.incqs.fiocruz.br/index.p.../1596/1152
As Brasil has the most death toll in South America, this could be the next country to take action with Leronlimab to fight Covid-19.
Excerpt:
As shown in Table 3, a multiplicity of immunosuppressive drugs or
therapies have been used to reverse the cytokine release syndrome in Covid-19 trials. The tested immunomodulating and/or anti-inflammatory drugs cover a broad range of compounds and modes of action such as classical glucocorticoids or agonists of glucocorticoid receptor (dexamethasone, methylprednisolone, budesonide), biologicals including some of the newest ones (anti-IL-6 monoclonal antibodies tocilizumab and siltuximab, the antibody against CCR5 receptors on T-lymphocytes leronlimab , and an antibody against cytokine fusion protein CD24Fc), ruxolitinib (Janus kinase JAK1 and JAK2 selective inhibitor and blocker of cytokine signalling)
Table 3:
Leronlimab (PRO 140)
Antibody against chemokine CCR5 receptor on T-lymphocytes. Used to treat HIV infections
Severe or critical Covid-19 patients Q (n = 75, n = 390)
https://visaemdebate.incqs.fiocruz.br/index.p.../1596/1152
(3)
(0)
